Clinical trial
Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA…
NCT00202995 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Terminated
Key facts
| NCT number | NCT00202995 |
|---|---|
| Title | Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS |
| Official title | A Multi-Center, Randomized, Single-Blind, Parallel Group Study to Compare the Efficacy, Tolerability and Safety, of Copaxone® to That of High Dose Interferon (Betaseron® or Rebif®) in the Treatment of Relapsing Multiple Sclerosis Patients |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Relapsing Remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Glatiramer Acetate, Betaseron, Rebif |
| Enrollment | 91 |
| Start date | Jul 1, 2004 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Sep 20, 2005 |
| Last update posted | Oct 18, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: